Behind the rosiglitazone controversy

Expert Review of Clinical Pharmacology

Volumn 3, Issue 6, 2010, Pages 723-725

  Cheung, Bernard M Y ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADRENOMEDULLIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; UROTENSIN II;

ACUTE HEART INFARCTION; ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIARRHEA; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PERIPHERAL EDEMA; SIDE EFFECT; STROKE; TREATMENT INDICATION; WEIGHT GAIN;

EID: 78649381418     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.126     Document Type: Note

References (4)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
2. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170(14), 1191-1201 (2010).
3. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4), 411-418 (2010).
4. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for Type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681), 2125-2135 (2009).